Challenges and New Technologies of Oral Controlled Release

Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice

Volumn , Issue , 2010, Pages 257-277

  Chen, Xiaoming ^a   Wen, Hong ^b   Park, Kinam ^c  

^a OSI Pharmaceuticals   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c PURDUE UNIVERSITY   (United States)

Author keywords

Challenges and new technologies of oral controlled release; Hot melt extrusion (HME) process in plastic, rubber and food industry HME, as powerful process technology for drug delivery; Oral controlled delivery for water insoluble drugs

Indexed keywords

EID: 84863758180     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470640487.ch16     Document Type: Chapter

References (90)

1. Rao VM, Haslam JL, Stella VJ. Controlled and complete release of a model poorly water-soluble drug, prednisolone, from hydroxypropyl methylcellulose matrix tablets using (SBE)7m-b-cyclodextrin as a solubilizing agent. J. Pharm. Sci. 2001;90:807-816.
2. Sotthivirat S, Haslam JL, Stella VJ. Controlled porosityosmotic pump pellets of a poorly water-soluble drug using sulfobutylether-beta-cyclodextrin, (SBE) 7M-beta-CD, as a solubilizing and osmotic agent. J. Pharm. Sci. 2007; 96:2364-2367.
3. Lee KR, Kim EJ, Seo SW, Choi HK. Effect of poloxamer on the dissolution of felodipine and preparation of controlled release matrix tablets containing felodipine. Arch. Pharm. Res. 2008;31:1023-1028.
4. Mehramizi A, Alijani B, Pourfarzib M, Dorkoosh FA, Rafiee-Tehrani M. Solid carriers for improved solubility of glipizide in osmotically controlled oral drug delivery system. Drug Dev. Ind. Pharm. 2007;33:812-823.
5. Hong SI, Oh SY. Dissolution kinetics and physical characterization of three-layered tablet with poly(ethylene oxide) core matrix capped by Carbopol. Int. J. Pharm. 2008;356: 121-129.
6. Tanaka N, Imaia K, Okimotob K, Uedaa S, Tokunagab Y, Ohikea A, Ibukic R, Higakid K, Kimura T. Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine (I). J. Control. Release 2005;108:386-395.
7. Tanaka N, Imaia K, Okimotob K, Uedaa S, Tokunagab Y, Ohikea A, Ibukic R, Higakid K, Kimura T. Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine (II): in vivo evaluation. J. Control. Release 2006; 112:51-56.
8. Pederson AV. Erosion-based drug delivery. Manuf. Chem. 2006; 11:1-6.
9. Washington N, Wilson CG. Erosion-based delivery. Drug Deliv. Technol. 2006;10:71-74.
10. Andrews GP, Laverty TP, Jones DS. Mucoadhesive polymeric platforms for controlled drug delivery. Eur. J. Pharm. Biopharm. 2009;71:505-518.
11. Tao Y, Lu Y, Sun Y, Gu B, Lu W, Pan J. Development of mucoadhesive microspheres of acyclovir with enhanced bioavailability. Int. J. Pharm. 2009;378:30-36.
12. Chavanpatil MD, Jain P, Chaudhari S, Shear R,Vavia PR. Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for ofloxacin. Int. J. Pharm. 2006; 316:86-92.
13. Varshosaz J, Tavakoli N, Roozbahani F. Formulation and in vitro characterization of ciprofloxacin floating and bioadhesive extended-release tablets. Drug Deliv. 2006;13:277-285.
14. Deshpande MC, Venkateswarlu V, Babu RK, Trivedi RK. Design and evaluation of oral bioadhesive controlled release formulations of miglitol, intended for prolonged inhibition of intestinal alpha-glucosidases and enhancement of plasma glucagon like peptide-1 levels. Int. J. Pharm. 2009;380:16-24.
15. Bigucci F, Luppi B, Monaco L, Cerchiara T, Zecchi V. Pectinbased microspheres for colon-specific delivery of vancomycin. J. Pharm. Pharmacol. 2009;61:41-46.
16. Grass GM. Simulation models to predict oral drug absorption from in vitro data. Adv. Drug Deliv. Rev. 1997;23:199-219.
17. Norris DA, Leesman GD, Sinko PJ, Grass GM. Development of predictive pharmacokinetic simulation models for drug discovery. J. Control. Release 2000;65:55-62.
18. Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv. Drug Deliv. Rev. 2001;50:S41-S67.
19. Lukacova V, Woltosz WS, Bolger MB. Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release, and intravenous data. AAPS J. 2009; 11:323-334.
20. Kuentz M, Nicka S, Parrotta N,Röthlisbergera D.Astrategy for preclinical formulation development using GastroPlusTM as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. Eur. J. Pharm. Sci. 2006;27:91-99.
21. Okumua A, DiMasob M, Löbenberg R. Computer simulations using GastroPlusTM to justify a biowaiver for etoricoxib solid oral drug products. Eur. J. Pharm. Biopharm. 2009;72:91-98.
22. Parrott N, Lave T. Prediction of intestinal absorption: comparative assessment of GASTROPLUS and IDEA. Eur. J. Pharm. Sci. 2002;17:51-61.
23. Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A, Tucker G. Population-based mechanistic prediction of oral drug absorption. AAPS J. 2009;11:225-237.
24. Polak S, Jamei M, Turner D. Prediction of the in vivo behaviour of modified release formulations of metoprolol from in vitro dissolution profiles using the ADAM model (SimCYP®v8). 10th European ISSX Meeting, May 2008, pp. 18-21.
25. Langer R, Peppas N. Advances in biomaterials, drug delivery, and bionanotechnology. AIChE J. 2003;49:2990-3006.
26. Malik DK, Baboota S, Ahuja A, Hasan S, Ali J. Recent Advances in protein and peptide drug delivery systems. Curr. Drug Deliv. 2007;4:141-151.
27. Sinha V, Singh A, Kumar RV, Singh S,Kumria R, Bhinge J. Oral colon-specific drug delivery of protein and peptide drugs. Crit. Rev. Ther. Drug Carrier Syst. 2007;24:63-92.
28. Morishita M, Aoki Y, Sakagami M, Nagai T, Takayama K. In situ ileal absorption of insulin in rats: effects of hyaluronidase pretreatment diminishing the mucous/glycocalyx layers. Pharm. Res. 2004;21:309-316.
29. Aoki Y, Morishita M, Asai K, Akikusa B, Hosoda S, Takayama K. Region-dependent role of the mucous/glycocalyx layers in insulin permeation across rat small intestinal membrane. Pharm. Res. 2005;22:1854-1862.
30. Aoki Y, Morishita M, Asai K, Akikusa B, Hosoda S, Takayama K. Region-dependent role of the mucous/glycocalyx layers in insulin permeation across rat small intestinal membrane. Pharm. Res. 2005;22:1854-1862.
31. Hamman JH, Enslin GM, Kotzé AF. Oral delivery of peptide drugs: barriers and developments. BioDrugs 2005;19: 165-177.
32. Hosny E, Al-Shora H, Elmazar M. Oral delivery of insulin from enteric-coated capsules containing sodium salicylate: effect on relative hypoglycemia of diabetic beagle dogs. Int. J. Pharm. 2002;237:71-76.
33. Sinha VR, Singh A, Kuma RV, Singh S, Kumria R, Bhinge JR. Oral colon-specific drug delivery of protein and peptide drugs. Crit. Rev. Ther. Drug Carrier Syst. 2007;24:63-92.
34. Morishita M, Morishita I, Takayama K, Machida Y, Nagai T. Site dependent effect of aprotinin, sodium caprate, Na2EDTA and sodium glycocholate on intestinal absorption of insulin. Biol. Pharm. Bull. 1993;16:68-72.
35. Lueben HL, Lehr CM, Rentel CO, Noach AB, Boer AG, Verhoel JC. Bioadhesive polymers for the peroral delivery of peptide drugs. J. Control. Release 1994;29:329-338.
36. Tozaki H, Nishioka J, Komoike J, Okada N, Fujita T, Muranishi S. Enhanced absorption of insulin and (Asu(1,7)) eel-calcitonin using novel azopolymer-coated pellets for colon-specific drug delivery. J. Pharm. Sci. 2001;90:89-97.
37. Rick S. Oral protein and peptide drug delivery. In Binghe W, Teruna S, Richard AS,editors. Drug Delivery: Principles and Applications, Wiley Interscience, New Jersey, 2005, p. 189.
38. Aungst B. Intestinal permeation enhancers. J. Pharm. Sci. 2000;89:429-442.
39. Lecluyse EL, Sutton SC. In vitro models for selection of development candidates. Permeability studies to define mechanisms of absorption enhancement. Adv. Drug Deliv. Rev. 1997;23:163-183.
40. Dong ZL, Lecluyse EL, Thakker DR. Dodecylphosphocholinemediated enhancement of paracellular permeability and cytotoxicity in Caco-2 cell monolayers. J. Pharm. Sci. 1999;88: 1161-1168.
41. Sood A, Panchagnula R. Peroral route: an opportunity for protein and peptide drug delivery. Chem. Rev. 2001; 101:3275-3303.
42. Noha NS, Natalie DE, Alessio F. Tight junction modulation and its relationship to drug delivery. Adv. Drug. Deliv. Rev. 2006; 58:15-28.
43. Karyekar CS, Fasano A, Raje S. Zonula Occludens toxin increases the permeability of molecular weight markers and chemotherapeutic agents across the bovine brain microvessel endothelial cells. J. Pharm. Sci. 2003;92:414-423.
44. Fasano A, Uzzau S. Modulation of intestinal tight junctions by zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model. J. Clin. Invest. 1997;99:1158-1164.
45. Peppas NA, Thomas JB, McGinty J. Molecular aspects of mucoadhesive carrier development for drug delivery and improved absorption. J. Biomater. Sci. Polym. Ed. 2009;20:1-20.
46. Mehta NM. Oral delivery and recombinant production of peptide hormones. Biopharm. Int. 2004;6:1-6.
47. Ziv E, Kidron M, Raz I, Krausz M, Blatt Y, Rotman A, Bar-On H. Oral administration of insulin in solid form to nondiabetic and diabetic dogs. J. Pharm. Sci. 1994;83:792-794.
48. Damgé C, Reis CP, Maincent P. Nanoparticle strategies for the oral delivery of insulin.Expert Opin. Drug Deliv. 2008;5:45-68.
49. Kipnes M, Dandona P, Tripathy D, Still JG, Kosutic G. Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes. Diabetes Care 2003;26:421-426.
50. Hashimoto M, Takada K, Kiso Y, Muranishi S. Synthesis of palmitoyl derivatives of insulin and their biological activities. Pharm. Res. 1989;6:171-176.
51. Kamei N, Morishita M, Chiba H, Kavimanda NJ, Peppas NA, Takayama K. Complexation hydrogels for intestinal delivery of interferon b and calcitonin. J. Control. Release, 2009; 134:98-102.
52. Polovic N, Velickovic TC. Novel formulations for oral allergen vaccination. Recent Pat. Infalmm. Allergy Drug Discov. 2008; 2:215-221.
53. Vipond J, Cross ML, Lambeth MR, Clark S, Aldwell FE, Williams A. Immunogenicity of orally-delivered lipid-formulated BCG vaccines and protection against Mycobacterium tuberculosis infection. Microbes Infect. 2008;10:1577-1581.
54. Nayak B, Panda AK, Ray P, Ray AR. Formulation, characterization and evaluation of rotavirus encapsulated PLA and PLGA particles for oral vaccination. J. Microencapsul. 2008;6:1-12.
55. Saha DWY. Therapeutic potential of RNA interference for neurological disorders. Life Sci. 2006;79:1773-1780.
56. Crowe S. Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS 2003;17 (Suppl 4): 103-1055.
57. Hogrefe RI, Lebedev AV, Zon G, Pirollo KF, Rait A, Zhou Q,Yu W, Chang EH. Chemically modified short interfering hybrids (siHYBRIDS): nanoimmunoliposome delivery in vitro and in vivo for RNAi of HER-2. Nucleosides Nucleotides Nucleic Acids 2006;25:889-907.
58. Kumar P, Ban HS, Kim SS, Wu H, Pearson T, Greiner DL, Laouar A, Yao J, Haridas V, Habiro K, Yang YG, Jeong JH, Lee KY, Kim YH, KimSW, Peipp M, Fey GH, Manjunath N, Shultz LD, Lee SK, Shankar P. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008;134:577-586.
59. Kim WJ, Kim SW. Efficient SiRNA delivery with non-viral polymeric vehicles. Pharm. Res. 2009;26:657-666.
60. Bumcrot D, Manoharan M, Koteliansky V, Sah DW. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol. 2006;2:711-719.
61. Chokshi R, Zia H. Hot-melt extrusion technique: a review. Iranian J. Pharm. Res. 2004;3:3-16.
62. Coppens KA, Hall MJ, He VY, Koblinski BD, Larsen PS, Read MD, Shrestha V. Hypromellose and polyethylene oxide blends in hot melt extrusion. Dow Chemical Form 2006,198-02152.
63. Zhu Y, Shah N,Waseem MA, Martin I, McGinity J. Controlled release of a poorly water-soluble drug from hot-melt extrudates containing acrylic polymers. Drug Dev. Ind. Pharm. 2006; 32:569-583.
64. Kang JJ, Lee SH, Jung TS, Heo YM. 200 mm-class polymeric microneedle fabricated by a micro injection molding technique. Nanotechnology 2007;3:371-374.
65. Quinten T, Beer TD, Vervaet C, Remon JP. Evaluation of injection moulding as a pharmaceutical technology to produce matrix tablets. Eur. J. Pharm. Biopharm. 2009; 71:145-154.
66. Anonymous. HP takes inkjet technology to medical device market. HP news room URL: http://h41131.www4.hp.com/vn/en/stories/hp-takes-inkjet-technology-to-medical-devicemarket22928.html.
67. Igawa K, Chung UI, Tei Y. Custom-made artificial bones fabricated by an inkjet printing technology. Clin. Calcium 2008;18:1737-1743.
68. Tarcha PJ, Verlee D, Hui HW, Setesak J, Antohe B, Radulescu D, Wallace D. The application of ink-jet technology for the coating and loading of drug-eluting stents. Ann. Biomed. Eng. 2007;35:1791-1799.
69. Xu T, Rohozinski J, Zhao W, Moorefield EC, Atala A, Yoo JJ. Inkjet-mediated gene transfection into living cells combined with targeted delivery. Tissue Eng. A 2009;15:95-101.
70. Mironov V, Kasyanov V, Drake C, Markwald RR. Organ printing: promises and challenges. Regen. Med. 2008;3(1): 93-103.
71. Campbell PG, Weiss LE. Tissue engineering with the aid of inkjet printers. Expert Opin. Biol. Ther. 2007;7:1123-1127.
72. Abukawa H, Papadaki M, Abulikemu M, Leaf J, Vacanti JP, Kaban LB, Troulis MJ. The engineering of craniofacial tissues in the laboratory: a review of biomaterials for scaffolds and implant coatings. Dent. Clin. North Am. 2006;50:205-216.
73. Lin S, Chao PY, Chien YW, Sayani S, Kuma S, Mason M,Wes T, Yang A, Monkhouse D. In vitro and in vivo evaluations of biodegradable implants for hormone replacement therapy: effect of system design and PK-PD relationship. AAPS PharmSciTech 2001;2:E16.
74. Sachs EM, Cima MJ,Williams P, Brancazio D, Cornie J. Threedimensional printing: rapid tooling and prototypes directly from a CAD model. J. Eng. Ind. 1991;114:481-488.
75. Yu DG, Yang XL, Huang WD, Liu J,Wang YG, Xu H. Tablets with material gradients fabricated by three-dimensional printing. J. Pharm. Sci. 2007;96:2446-2456.
76. Katstra WE, Palazzolo RD, Rowe CW, Giritlioglu B, Teung P, Cima MJ. Oral dosage forms fabricated by three dimensional printing. J. Control. Release 2000;66:1-9.
77. Obara S, Maruyama N, Nishivama Y, Kokubo H. Dry coating: an innovative enteric coating method using a cellulose derivative. Eur. J. Pharm. Biopharm. 1999;47:51-59.
78. Cerea M, Zheng W, Young C, McGinity JW. A novel powder coating process for attaining taste masking and moisture protective films applied to tablets. Int. J. Pharm. 2004; 279:127-139.
79. Zhu J, Luo YF, Ma Y, Zhang H. Direct coating solid dosage forms using powdered materials. US Patent Application 20070128274, 2007.
80. Ghimirea M, McInnesa FJ,Watsona DG, Mullena AB, Stevens HNE. In vitro/in vivo correlation of pulsatile drug release from press-coated tablet formulations: a pharmacoscintigraphic study in the beagle dog. Eur. J. Pharm. Biopharm. 2007; 67:515-523.
81. Gohel MC, Parikh RK, Nagori SA, Dabhi MR. Design of a potential colonic drug delivery system of mesalamine. Pharm. Dev. Technol. 2008;13:447-456.
82. Lin SY, Li MJ, Lin KH. Hydrophilic excipients modulate the time lag of time-controlled disintegrating press-coated tablets. AAPS PharmSciTech 2004;5:e54.
83. Ozeki Y, Ando M, Watanabe Y, Danjo K. Evaluation of novel one-step dry-coated tablets as a platform for delayed-release tablets. J. Control. Release 2004;95:51-60.
84. Sakurai M, Ozeki Y, Ando M, Okamoto H, Danjo K. Drug delivery to the colon using novel one-step, dry-coated tablets (OSDrC). Yakugaku Zasshi 2008;128:951-957.
85. Moghadam SH, Wang HW, Saddar El-Leithy E, Chebli C, Cartilier L. Substituted amylose matrices for oral drug delivery. Biomed. Mater. 2007;2:S71-S77.
86. Nabaisa T, Brouilleta F, Kyriacosc S, Mrouehc M, Amores da Silvad P, Batailleb B, Cheblia C, Cartiliera L. High-amylose carboxymethyl starch matrices for oral sustained drug-release: in vitro and in vivo evaluation. Eur. J. Pharm. Biopharm. 2007;65:371-378.
87. Brouilleta F, Batailleb B, Cartiliera L. High-amylose sodium carboxymethyl starch matrices for oral, sustained drug-release: formulation aspects and in vitro drug-release evaluation. Int. J. Pharm. 2008;356:52-60.
88. Korhonen O, Raatikainen P, Harjunen P, Nakari J, Suihko E, Peltonen S, Vidgren M, Paronen P. Starch acetates-multifunctional direct compression excipients. Pharm. Res. 2000; 12:1138-1143.
89. Jani GK, Shah DP. Evaluation of mucilage of Hibiscus rosasinensis Linn as rate controlling matrix for sustained release of diclofenac. Drug Dev. Ind. Pharm. 2008; 34:807-816.
90. Novosel'skaya IL, Vorropaeva NL, Semenova LN, Rashidova SS. Trends in the science and applications of pectins. Chem. Nat. Compd. 2000;36:1-10.